{"id":30893,"date":"2025-03-29T16:24:13","date_gmt":"2025-03-29T08:24:13","guid":{"rendered":"https:\/\/flcube.com\/?p=30893"},"modified":"2025-03-29T16:24:15","modified_gmt":"2025-03-29T08:24:15","slug":"eisai-transfers-pariet-rights-in-china-to-cbc-group-controlled-peak-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30893","title":{"rendered":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma"},"content":{"rendered":"\n

Japan-based Eisai (TYO: 4523<\/a>) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group.<\/p>\n\n\n\n

Pariet’s Market Presence<\/strong>
Pariet, with rabeprazole as its active ingredient, has been a leading prescription drug for gastrointestinal disorders such as gastric and duodenal ulcers, reflux esophagitis, and Zollinger-Ellison syndrome. Eisai first introduced Pariet to the Chinese market in February 2000 and has since dominated the domestic market. However, with the rise of generic drug manufacturers, the market has become highly competitive, with 16 companies now approved to produce rabeprazole sodium enteric-coated tablets.<\/p>\n\n\n\n

Market Competition and Share<\/strong>
Public data shows that Jumpcan Pharmaceutical has taken the lead with over 40% market share, pushing Eisai to the second position with approximately 16%. Rundu Pharma follows with over 10% market share. In the 2022 hospital terminal market, the top three companies were Jumpcan Pharmaceutical, Eisai, and C&O Pharmaceutical Technology, with market shares of 31.76%, 12.17%, and 9.91% respectively.<\/p>\n\n\n\n

Volume-Based Procurement (VBP) and Pricing<\/strong>
Rabeprazole sodium enteric-coated tablets faced a competitive landscape in the ninth batch of VBP, with nine domestic and one imported product competing. In 2022, sales of rabeprazole oral formulations in public medical institutions reached 3.8 billion RMB. During the VBP, the highest tender price for the 10mg specification was 0.7647 RMB per tablet, and for the 20mg specification, it was 1.3 RMB per tablet. Zhuhai Rundu Pharma secured the top position in the proposed bid winning list with a bid price of approximately 0.22 RMB per table. Companies such as Chongqing YaoPharma, Jincheng Haisi Pharmaceutical, Shandong Xinhua Pharmamceutical, Shanghai Anbison Lab. Co., Ltd., Hunan Jiudian Pharmaceutical Co.,Ltd., Jiangxi Shanxiang Pharm Co. Ltd., and Jumpcan Pharmaceutical all won bids with price reductions exceeding 60%.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton…<\/p>\n","protected":false},"author":1,"featured_media":30896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[3394,3945,350,3947,3949,2418,3944,3948,3950,347,3946],"class_list":["post-30893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-anbison-lab","tag-co-pharmaceutical-technology","tag-eisai","tag-haisi-pharmaceutical","tag-jiudian-pharmaceutical","tag-jumpcan-pharmaceutical","tag-peak-pharmaceutical","tag-rundu-pharma","tag-shanxiang-pharm","tag-xinhua-pharmaceutical","tag-yaopharma"],"yoast_head":"\nEisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30893\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30893\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-29T08:24:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-29T08:24:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma\",\"datePublished\":\"2025-03-29T08:24:13+00:00\",\"dateModified\":\"2025-03-29T08:24:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893\"},\"wordCount\":298,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2903-png.webp\",\"keywords\":[\"Anbison Lab\",\"C&O Pharmaceutical Technology\",\"Eisai\",\"Haisi Pharmaceutical\",\"Jiudian Pharmaceutical\",\"Jumpcan Pharmaceutical\",\"Peak Pharmaceutical\",\"Rundu Pharma\",\"Shanxiang Pharm\",\"Xinhua Pharmaceutical\",\"YaoPharma\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30893#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30893\",\"name\":\"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2903-png.webp\",\"datePublished\":\"2025-03-29T08:24:13+00:00\",\"dateModified\":\"2025-03-29T08:24:15+00:00\",\"description\":\"Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30893\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2903-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2903-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30893#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma - Insight, China's Pharmaceutical Industry","description":"Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30893","og_locale":"en_US","og_type":"article","og_title":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30893","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-29T08:24:13+00:00","article_modified_time":"2025-03-29T08:24:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30893#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30893"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma","datePublished":"2025-03-29T08:24:13+00:00","dateModified":"2025-03-29T08:24:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30893"},"wordCount":298,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","keywords":["Anbison Lab","C&O Pharmaceutical Technology","Eisai","Haisi Pharmaceutical","Jiudian Pharmaceutical","Jumpcan Pharmaceutical","Peak Pharmaceutical","Rundu Pharma","Shanxiang Pharm","Xinhua Pharmaceutical","YaoPharma"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30893#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30893","url":"https:\/\/flcube.com\/?p=30893","name":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30893#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","datePublished":"2025-03-29T08:24:13+00:00","dateModified":"2025-03-29T08:24:15+00:00","description":"Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30893#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30893"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30893#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","width":1080,"height":608,"caption":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30893#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2903-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30893"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30893\/revisions"}],"predecessor-version":[{"id":30897,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30893\/revisions\/30897"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30896"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}